

Date and Time: *Thursday 30 April 2015, 10am-4pm*

Minutes: Confirmed

Cirrhosis Guideline Development Group Meeting 8

Place: *Rosenheim & Pickering room, Royal College of Physicians, 11 St Andrews Place, Regent's Park, London NW1 4LE*

Present:	Phil Harrison (Chair)	Consultant Hepatologist
	Marsha Morgan	Principle Research Fellow/Honorary Consultant Physician
	Susan McRae	Patient/Carer Member
	Andrew Fowell	Consultant Gastroenterologist and Hepatologist
	Lynda Greenslade	Clinical Nurse Specialist in Hepatology
	Valerie Ross	Lead Pharmacist, Hepatology
	Mark Hudson	Consultant Hepatologist
	Iain Brew	General Practitioner
	Gerri Mortimore	Lead CNS Liver
	John O'Grady (co-optee)	Consultant transplant hepatologist
	Andrew Langford	Patient/Carer Member
	Emily Davies	Senior Research Fellow, NCGC
	Gill Ritchie	Associate Director, NCGC
	Stacey Lockyer	Research Fellow, NCGC
	Lefteris Floros	Health Economist, NCGC
	Martin J Harker	Senior Health Economist, NCGC
	Ben Pordes	Project Manager, NCGC

Apologies:

Brian Hogan, Specialist Registrar in Hepatology and Intensive Medicine

Caroline Keir, Guidelines Commissioning Manager, NICE

Notes

1. The Chair welcomed the group to the eighth meeting of this GDG. Apologies were received from BH and CK. The Chair reviewed and requested updates to the declarations of interest register. The Chair declared that in relation to the **previous** declarations recorded in the DOI register, for this meeting:
 - MH and LG to withdraw from discussion regarding Q19 on acute hepatic encephalopathy

New declarations of interest received for this GDG meeting include:

GDG Declarations of Interest			
N.B. The Chair and GDG members were recruited to this guideline using NICE DOI policy published Oct 2008.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chairs action
AL	The British Liver Trust was gifted a Fibroscan machine by Norgine the producer of Targaxan	Non-personal pecuniary interest	Withdraw from discussion of Q19 – acute hepatic encephalopathy

2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
3. LF presented parameters for the health economic model to the GDG.
4. The GDG discussed the draft LETR for early detection of hepatocellular carcinoma
5. The GDG discussed the draft LETR for surveillance testing for detection of varices.
6. The GDG discussed the draft LETR for diagnostic tests
7. ED presented the exclusion criteria for the upcoming review on acute hepatic encephalopathy
8. ED presented the clinical evidence report for severity risk tools. LF presented the health economic evidence.
9. There was no other business.

Date, time and venue of the next meeting

GDG9: Thursday 25th June, Boardroom, NCGC, 180 Great Portland St, London W1W 5QZ